These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30228208)

  • 1. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
    Henry KE; Dacek MM; Dilling TR; Caen JD; Fox IL; Evans MJ; Lewis JS
    Clin Cancer Res; 2019 Jan; 25(1):166-176. PubMed ID: 30228208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive
    Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
    J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Knight JC; Mosley MJ; Bravo LC; Kersemans V; Allen PD; Mukherjee S; O'Neill E; Cornelissen B
    Clin Cancer Res; 2017 Nov; 23(21):6498-6504. PubMed ID: 28774899
    [No Abstract]   [Full Text] [Related]  

  • 5. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.
    Wang B; Fan P; Zhao J; Wu H; Jin X; Wu H
    J Exp Clin Cancer Res; 2018 Sep; 37(1):224. PubMed ID: 30201002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
    Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
    [No Abstract]   [Full Text] [Related]  

  • 8. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma.
    Joseph J; Radulovich N; Wang T; Raghavan V; Zhu CQ; Tsao MS
    Oncogene; 2020 Jan; 39(2):308-321. PubMed ID: 31477830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
    Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
    Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concepts to Target MYC in Pancreatic Cancer.
    Wirth M; Mahboobi S; Krämer OH; Schneider G
    Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
    Diehl JN; Hibshman PS; Ozkan-Dagliyan I; Goodwin CM; Howard SV; Cox AD; Der CJ
    Adv Cancer Res; 2022; 153():101-130. PubMed ID: 35101228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice.
    Sato T; Shibata W; Hikiba Y; Kaneta Y; Suzuki N; Ihara S; Ishii Y; Sue S; Kameta E; Sugimori M; Yamada H; Kaneko H; Sasaki T; Ishii T; Tamura T; Kondo M; Maeda S
    Cancer Sci; 2017 Nov; 108(11):2156-2165. PubMed ID: 28837246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
    Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
    Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR dependency in pancreatic cancer.
    Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
    Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.